Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$3.16 USD
+0.22 (7.48%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $3.15 -0.01 (-0.32%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 41 - 60 ( 197 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-2056 Granted Orphan Drug Designation by FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; UPGRADE Interim Combo Data Expected 4Q22; Discontinuing XMT-1592
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Safety Data Update for UpRi in Ovarian Cancer Expansion Cohort
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Data at SGO UPGRADEs Our Expectations for UpRi
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Riding High on UpRi With All Platforms Engaged
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Mersana DolinÂ’ Out Dolasynthen ADCs to Janssen
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Priorities and Milestones for 2022 Outlined
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; UPLIFT Registration Study Continues to Enroll Patients; UP-NEXT Study to Initiate Next Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department